Bempedoic Acid Gains CV Risk Reduction Indication
The drug becomes the first nonstatin, LDL cholesterol-lowering agent indicated for the primary prevention of CVD.
Source: tctmd.com
Page 27 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Human Use Today - Breaking & Trending Today
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease -March 13, 2024 at 04:03 am EDT
PREVENAR 20® offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of...
Source: marketscreener.com
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease | Nation/World
NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--
Source: bdtonline.com
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
NEW YORK, March 13, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
Source: yahoo.com
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease | Region
NEW YORK--(BUSINESS WIRE)--Mar 13, 2024--
Source: eagletribune.com